Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop

Despite Obvious Clinical Benefits, Successful Commercialization Remains Elusive

Executive Summary

As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.

You may also be interested in...



The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy

2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.

Stock Watch: Gene Therapy’s Bittersweet Approvals

There are instances where the FDA approval of an unpartnered drug is the worst outcome for a biotech company. We may have just seen the first such gene therapy example.

Stock Watch: Risk And The Pharmaceutical Discount Rate

In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel